インタビュー
「Oral Abstract Session：ハイライトオブザデイIII―肺癌の局所治療とアジュバント療法」の演者 Antoinette J. Wozniak氏に聞く
ハイライトオブザデイは，前日のオーラル口演のハイライトをその領域のオーソリティが簡略に解説するというセッションだ。Antoinette J. Wozniak氏（Karmanos癌研究所）がポイント解説を行ったのは，肺癌の局所治療とアジュバント療法をテーマとした9演題。インタビューに応えてくれたWozniak氏は，これらのなかで，個々の患者の治療薬への反応性を予測する分子マーカーに最も興味を引かれたと語った。（佐藤生美雄）
| 編集部 | 解説されたなかで，先生が最も興味深かったことを教えてください。 |
| Wozniak氏 |  |
Get the Flash Player to see this player.
|
Download（クリックで保存） |
molecular marker：分子マーカー
predicts：予測因子
adjuvant treatment：アジュバント療法（術後の補助化学療法）
prophylactic cranial irradiation：予防的頭蓋照射
poor accrual：（脳転移の）発生が少ない
brain metastasis：脳転移
I think that the most interesting part were the molecular marker abstracts. I think we're trying to determine what predicts for response to treatment, and I think in terms of customizing treatment that's the way we have to go. I also think that the update of the JBR.10 adjuvant trial supports adjuvant treatment. I think that was important. I don't think we have any data that would support neoadjuvant treatment right now in early stage disease. The other trial that I think was important was the prophylactic cranial irradiation trial. Unfortunately it closed early because of poor accrual, and unfortunately it, although it - the incidence of brain metastasis disease is reduced, it doesn't improve survival, and probably doesn't support a change in practice.
| 編集部 | 分子マーカーについては，どのような期待をお持ちですか？ |
| Wozniak氏 | |
Get the Flash Player to see this player.
|
Download（クリックで保存） |
patient resources：（検査結果や病歴などを含めた）患者情報
appropriately：適切に
I think most of the trials in the future are going to try to look at molecular markers as part of them because we need this to be able to determine who responds best to which type of treatment. And that way, you know, patient resources can be used more appropriately, and hopefully we can improve our outcomes with some of these trials.
| 編集部 | 学会参加者に臨床現場に持ち帰ってほしいこととは何でしょうか？ |
| Wozniak氏 | |
Get the Flash Player to see this player.
|
Download（クリックで保存） |
maintenance therapy：維持療法
pemetrexed：ペメトレキセド（商品名：アリムタ）
erlotinib：エルロチニブ（商品名：タルセバ）
gefitinib：ゲフィチニブ（商品名：イレッサ）
EGFR-TKI：上皮成長因子受容体チロシンキナーゼ阻害薬
I think there's a couple of take-home points. One of... I think with the session I just described, I explained what I thought was important. But overall, I think the use of maintenance therapy is going to be a big issue. And that is maintenance with pemetrexed or erlotinib. Those studies were presented. There are some newer drugs. And I think one of the important things again is to determine molecular markers, and I think everybody would agree that at least before treating someone with an EGFR-TKI, like erlotinib or gefitinib that we need mutational analysis, especially if we're using it in first-line treatment.
